Showing 6481-6490 of 8236 results for "".
- Fewer Cases of Melanoma, Cancers in Extracutaneous Sites Seen in Patients with Atopyhttps://practicaldermatology.com/news/fewer-cases-of-melanoma-cancers-in-extracutaneous-sites-seen-in-patients-with-atopy/2461591/Fewer cases of melanoma are observed in people with a history of atopic diseases, such as allergic asthma or rhinitis, than in nonatopic people, according to a new study in Melanoma Research. Specifically, the risk of melanoma in people with atopy was up to 50% lower than
- U.S. FDA: Renuvion Cleared to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissuehttps://practicaldermatology.com/news/us-fda-renuvion-cleared-to-coagulate-and-contract-soft-tissues-including-subcutaneous-tissue/2461590/The U.S. Food and Drug Administration (FDA) has cleared the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. (Soft tissue includes subcutaneous tissue.) “We are pleas
- BeautyHealth Acquires SkinStylushttps://practicaldermatology.com/news/beautyhealth-acquires-skinstylus/2461579/The Beauty Health Company is set to acquire SkinStylus, a US Food and Drug Adminstrayion -cleared microneedling device. The agreement represents a key step forward in BeautyHealth’s portfolio build-up strategy. Upon successful integration of SkinStylus into the BeautyHealth
- Study: Plugging Immune Cell Leakage from Tumors Could Improve MelanomaTreatmenthttps://practicaldermatology.com/news/study-plugging-immune-cell-leakage-from-tumors-could-improve-melanomatreatment/2461578/The number of specialized immune cells available for fighting skin cancer double when a new treatment blocks their escape from melanoma tumors, according to new research out of NYU Langone Health’s Perlmutter Cancer Center Combining a chemical blocker of immune cell exit with
- Celluma Light Therapy Headquarters Moves to Tustin, Californiahttps://practicaldermatology.com/news/celluma-light-therapy-headquarters-moves-to-tustin-calif/2461570/BioPhotas, Inc., the maker of the Celluma Series of light therapy devices, is moving its corporate headquarters and manufacturing operations from Anaheim to Tustin, Calif. The new headquarters boasts 25,000 square feet of office and warehouse space, facilitating continued gro
- Cetaphil Launches Initiative to Raise Awareness of Connection Between Clothing and Sensitive Skinhttps://practicaldermatology.com/news/cetaphil-launches-initiative-to-raise-awareness-of-connection-between-clothing-and-sensitive-skin/2461567/Cetaphil announced it is launching a new initiative this month that aims to raise awareness of the connection between our clothes and skin. The initiative includes a partnership with Hillary Taymour, designer and founder of fashion house Collina Strada, and board-certified dermatologist
- ASA Renews Support of SPOTS Programhttps://practicaldermatology.com/news/asa-renews-support-of-spots-program/2461565/The American Skin Association (ASA) announced the renewal of its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a community outreach program designed to teach students from preschool through high school about the importance of early detectio
- Experts React to Approval of Pfizer’s CIBINQO for Teens With Refractory ADhttps://practicaldermatology.com/news/fda-oks-pfizers-cibinqo-for-teens-with-refractory-ad/2461560/The US FDA has approved a supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib, Pfizer). This move expands the drug's indication to include adolescents (12 to < 18 years) with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately contr
- Povorcitinib Produces Lasting Results in HShttps://practicaldermatology.com/news/povorcitinib-produces-lasting-results-in-hs/2461557/Longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms in a phase 2 study of hidradenitis suppurativa (HS) patients. Povorcitinib is an oral JAK1 inhibitor. These data were presented as an oral presentation at th
- Takeda Completes Acquisition of Nimbus’ TYK2 Subsidiaryhttps://practicaldermatology.com/news/takeda-completes-acquisition-of-nimbus-tyk2-subsidiary/2461552/Takeda has expanded its psoriasis treatment portfolio after completing its acquisition of Nimbus Lakshmi from Nimbus Therapeutics in a deal worth up to $6 billion. Under the agreement, which was announced on December 13, 2022, Takeda will acquire TAK-279, formerly known at Nim